Global Angiotensin Converting Enzymes (ACE) Inhibitors Market Growth, Share, Size, Trends and Forecast (2024 - 2030)

By Drugs;

Benazepril, Perindopril, Trandolapril, Captopril, Enalaopril, Lisinopril, Ramipril and Others.

By Application;

Hypertension, Coronary artery disease, Heart failure, Scleroderma, Migraine and Chronic kidney disease.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2020 - 2030).
Report ID: Rn145884197 Published Date: May, 2024 Updated Date: June, 2024


Global Angiotensin Converting Enzymes (ACE) Inhibitors Market (USD Million), 2020 - 2030

In the year 2023, the Global Angiotensin Converting Enzymes (ACE) Inhibitors Market was valued at USD 8,260.45 million. The size of this market is expected to increase to USD 10,870.18 million by the year 2030, while growing at a Compounded Annual Growth Rate (CAGR) of 4%.

Angiotensin Converting Enzyme (ACE) inhibitors serve as essential therapeutic agents, playing a significant role in the regulation of blood pressure, vascular tone, and fluid balance within the body. These medications inhibit the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, thereby dilating blood vessels, reducing blood pressure, and mitigating the progression of cardiovascular diseases such as hypertension, heart failure, and post-myocardial infarction.

The market for ACE inhibitors is propelled by several factors, including the high prevalence of cardiovascular diseases globally, the increasing incidence of hypertension and related risk factors such as obesity and diabetes, and the growing aging population susceptible to cardiovascular complications. Additionally, the expanding awareness of the importance of blood pressure management and preventive healthcare measures further drives the demand for ACE inhibitors as first-line therapy in the treatment of hypertension and heart failure.

Ongoing research and development efforts aimed at expanding the clinical indications and therapeutic applications of ACE inhibitors contribute to market growth. These efforts include investigating the efficacy of ACE inhibitors in the management of renal diseases such as diabetic nephropathy and proteinuria, as well as exploring their potential benefits in preventing cardiovascular events and improving outcomes in patients with acute coronary syndromes.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Drugs
    2. Market Snapshot, By Application
    3. Market Snapshot, By Region
  4. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Aging Population

        2. Rising Hypertension Prevalence

        3. Cardiovascular Disease Burden

      2. Restraints
        1. Patent Expiry

        2. Side Effects

        3. Regulatory Hurdles

      3. Opportunities
        1. Emerging Markets Expansion

        2. Combination Therapies Development

        3. Renal Disease Management

    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Drugs, 2020 - 2030 (USD Million)
      1. Benazepril

      2. Perindopril

      3. Trandolapril

      4. Captopril

      5. Enalaopril

      6. Lisinopril

      7. Ramipril

      8. Others

    2. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Application, 2020 - 2030 (USD Million)
      1. Hypertension

      2. Coronary artery disease

      3. Heart failure

      4. Scleroderma

      5. Migraine

      6. Chronic kidney disease

    3. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Geography, 2020 - 2030 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Novartis AG
      2. Pfizer Inc.
      3. Merck & Co.
      4. AstraZeneca
      5. Sanofi
      6. Boehringer Ingelheim
      7. GlaxoSmithKline
      8. Lupin Limited
      9. Torrent Pharmaceuticals Ltd.
  7. Analyst Views
  8. Future Outlook of the Market